A KFF poll also suggests half of the respondents who had tried these weight loss meds no longer took them, with many reporting difficulties paying for these drugs.
The cost of expanding US Medicare prescription drug coverage to pay for expensive, new obesity medications could be catastrophic, health economists warned in a report published on Saturday.
Even with new federal caps on Medicare pay for insulin, people with diabetes need to choose insurance plans carefully to get the most help in managing drug costs, experts say.
US regulators have put some of the new clozapine risk evaluation and mitigation strategy program on temporary hold because of start-up difficulties, including long telephone wait times.